Panakt

Primary antibodies against ADAM8, EGFR, CCL2, and Akt (panAkt and pAkt S473) were obtained from Proteintech; p-EGFR, ERK1/2 (panERK and pERK1/2 Tyr 202/204) from Cell Signaling Technology (Danvers, MA, USA); HB-EGF from ABclonal technology (Woburn, MA, USA). Iba-1, GFAP, and CD206 were purchased from Abcam (Cambridge, UK). Secondary antibodies were listed in the Supplementary Data Table S1 together with primary antibodies. Temozolomide was purchased from Selleckchem (Houston, TX, USA). As an EGFR inhibitor, we used Erlotinib (Selleckchem).

Primary antibodies against phospho-AKT (S473), pan-AKT, phospho-FoxO3a (S253), totalFoxO3a, phospho-p65 (S276), total-p65, cleaved-caspase3, cleaved-caspase1, cleaved-PARP1, LC3 and p62 were purchased from Cell Signaling Technology (Boston, Massachusetts, USA), total-caspase3, PAR and p-MLKL(S358) was purchased from abcam (Cambridge, UK), p53, PARP1, AIF, pan-AKT, totalFoxO3a, total-p65, GPX4 and β-actin were purchased from proteintech (Wuhan, Hubei, China), Cox IV, H3 and HRP conjugated anti-rabbit/mouse secondary antibodies were purchased from Abbkine (Wuhan, Hubei, China). Lipofectamine 2000 was purchased from Thermo Fisher Scientific (Waltham, Massachusetts, USA). AKT inhibitor SC66, TIC10, autophagy inhibitor CQ, ULK101, pan-caspase inhibitor Z-VAD-FMK and PARP1 inhibitor 3AB were purchased from Selleck (Houston, Texas, USA). CCK-8 kit was from 7 Sea Biotech (Shanghai, China). ROS inhibitor NAC was purchased from Topscience (Shanghai, China).